Metabolite profiles and mass balance of fuzuloparib, a novel poly (ADP-ribose) polymerase inhibitor, in subjects with advanced solid cancers.
Yicong BianJian MengSheng MaGuangze LiYuya WangShaorong LiLinsheng LiuChenrong HuangHua ZhangDafang ZhongLiyan MiaoPublished in: British journal of clinical pharmacology (2022)
C]fuzuloparib was well-tolerated at the study dose.
Keyphrases